Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy of HellenCare in Early-Stage Alzheimer's Disease
Sponsor: Peking University First Hospital
Summary
The goal of this clinical trial is to evaluate whether HellenCare, a multicomponent nutraceutical, improves cognitive and functional outcomes in patients with early-stage Alzheimer's disease (AD). The investigators will compare changes in outcomes between the HellenCare group and the placebo group to determine if the intervention is effective and safe.
Official title: The HEART Study: A Randomized, Double-Blind, Parallel Placebo-Controlled Trial on the Efficacy of HellenCare in Early-Stage Alzheimer's Disease
Key Details
Gender
All
Age Range
50 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-04-15
Completion Date
2025-12-31
Last Updated
2025-04-08
Healthy Volunteers
No
Conditions
Interventions
HellenCare
2 g, twice daily, to be taken on an empty stomach.
Placebo
2 g, twice daily, to be taken on an empty stomach.